In the Context of Developing the Pharmaceutical Sector Regionally and Internationally Head of the Egyptian Drug Authority Meets with Global Company MSD to Enhance Pharmaceutical Security and Explore Localization Opportunities ….. El-Ghamrawy: "We are working diligently to create a flexible regulatory environment that encourages investment and technology transfer." Dr. Ali El-Ghamrawy, Head of the Egyptian Drug Authority, held an official meeting with the global pharmaceutical company MSD, led by Dr. Hazem Abdel Samie, Managing Director of MSD Egypt, and Dr. Yasmine Maher, Director of Regulatory Affairs & Scientific Office Manager. The meeting aligns with the EDA’s ongoing efforts to strengthen cooperation with major international companies and develop Egypt’s pharmaceutical system. Discussions focused on future cooperation areas, including MSD’s performance in Egypt for 2024, mechanisms to facilitate the launch of new products, and opportunities to localize the production of biological medicines, aiming to reduce import costs and enhance pharmaceutical security. Both parties emphasized the importance of adopting flexible regulatory policies that support innovation and address patient needs, especially regarding high-tech imported products. Dr. El-Ghamrawy affirmed that the EDA prioritizes partnerships with leading international companies like MSD to improve the local pharmaceutical industry and boost its competitiveness regionally and globally. He highlighted the Authority’s strategy of supporting the localization of biological and advanced pharmaceutical technologies while maintaining access to innovative medicines without compromising quality or efficacy. He also underscored the importance of continued collaboration to support local manufacturing and technology transfer, address market challenges, and develop innovative solutions that enhance pharmaceutical security and achieve self-sufficiency. MSD representatives praised the EDA’s role in fostering an attractive investment climate and implementing flexible regulatory policies that expedite the registration and distribution of innovative medicines, ultimately contributing to improved healthcare outcomes in Egypt. The meeting was attended by Dr. Osama Hatem, EDA Assistant Chairman for Policy and International Cooperation and Supervisor of the Central Administration for Pharmaceutical Policies and Market Access and Dr. Hossam Abdullah, Assistant Chairman for Market Support and Continuity. This meeting reflects the EDA’s commitment to building strategic partnerships with global pharmaceutical leaders, promoting investment in local manufacturing and scientific research, and enhancing the pharmaceutical product registration and distribution system. These efforts aim to improve healthcare services and ensure sustainable availability of essential medicines for Egyptian patients. #EgyptianDrugAuthority #EgyptianDrugAuthorityMediaCenter #EgyptianPharmaceuticals
